JP2017529852A - Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 - Google Patents

Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 Download PDF

Info

Publication number
JP2017529852A
JP2017529852A JP2017516368A JP2017516368A JP2017529852A JP 2017529852 A JP2017529852 A JP 2017529852A JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017529852 A JP2017529852 A JP 2017529852A
Authority
JP
Japan
Prior art keywords
cancer
patient
mir
egfr
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017516368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529852A5 (enExample
Inventor
ラファエル、ティエボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IntegraGen SA
Original Assignee
IntegraGen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IntegraGen SA filed Critical IntegraGen SA
Publication of JP2017529852A publication Critical patent/JP2017529852A/ja
Publication of JP2017529852A5 publication Critical patent/JP2017529852A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017516368A 2014-09-26 2015-09-25 Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 Withdrawn JP2017529852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306490.5 2014-09-26
EP14306490.5A EP3000895A1 (en) 2014-09-26 2014-09-26 A method for predicting responsiveness to a treatment with an EGFR inhibitor
PCT/EP2015/072095 WO2016046365A1 (en) 2014-09-26 2015-09-25 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (2)

Publication Number Publication Date
JP2017529852A true JP2017529852A (ja) 2017-10-12
JP2017529852A5 JP2017529852A5 (enExample) 2018-10-25

Family

ID=51663116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516368A Withdrawn JP2017529852A (ja) 2014-09-26 2015-09-25 Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法

Country Status (10)

Country Link
US (1) US20170298442A1 (enExample)
EP (2) EP3000895A1 (enExample)
JP (1) JP2017529852A (enExample)
KR (1) KR20170086469A (enExample)
CN (1) CN107075583A (enExample)
AU (1) AU2015323744A1 (enExample)
BR (1) BR112017005421A2 (enExample)
CA (1) CA2961434A1 (enExample)
MX (1) MX2017003832A (enExample)
WO (1) WO2016046365A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976577C (en) 2015-02-11 2024-11-19 Univ Aarhus MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
WO2016134727A1 (en) * 2015-02-27 2016-09-01 Exiqon A/S A microrna-based method for assessing the prognosis of a prostate cancer patient
CN108034727B (zh) * 2018-01-18 2021-05-28 四川大学华西医院 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途
KR102480430B1 (ko) * 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
CN119303090B (zh) * 2024-10-15 2025-06-20 中国医学科学院北京协和医院 miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
US20120095030A1 (en) 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
SG176773A1 (en) * 2009-06-19 2012-01-30 Merck Patent Gmbh Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CA2856594A1 (en) 2011-11-25 2013-05-30 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
CN104046679B (zh) * 2013-03-11 2016-08-24 戴勇 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用

Also Published As

Publication number Publication date
AU2015323744A1 (en) 2017-04-27
CA2961434A1 (en) 2016-03-31
EP3198028A1 (en) 2017-08-02
CN107075583A (zh) 2017-08-18
US20170298442A1 (en) 2017-10-19
MX2017003832A (es) 2018-02-23
BR112017005421A2 (pt) 2017-12-12
WO2016046365A1 (en) 2016-03-31
EP3000895A1 (en) 2016-03-30
KR20170086469A (ko) 2017-07-26
EP3198028B1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
JP6342329B2 (ja) Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
US12077803B2 (en) MicroRNAs as biomarkers for endometriosis
KR101785795B1 (ko) 두경부암 예후 예측용 바이오마커 마이크로 rna
EP3198028B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
JP2011512785A (ja) ファルネシルトランスフェラーゼ治療に対する急性骨髄性白血病応答を決定する方法
US20160376661A1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
WO2010101916A1 (en) Methods for predicting cancer response to egfr inhibitors
CN101688243A (zh) 抗her2-靶向治疗中脂质激酶和与所述脂质激酶相关的信号转导途径的参与
JP2018500046A (ja) 血管内皮細胞増殖因子受容体阻害剤に対する感受性予測方法
US20150344961A1 (en) Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
JP5967699B2 (ja) 遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法
HK40011172A (en) Micrornas as biomarkers for endometriosis
HK40011172B (en) Micrornas as biomarkers for endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20181101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181101